Add office photos
Employer?
Claim Account for FREE
Glenmark Pharmaceuticals
3.9
based on 2.9k Reviews
Video summary
Company Overview
Company Locations
Working at Glenmark Pharmaceuticals
Company Summary
Glenmark Pharma is discovering advance therapies for a new world. Ceating centers of excellence in dermatology, oncology, etc
Overall Rating
3.9/5
based on 2.9k reviews
On-Par with
industry average
Critically rated for
Promotions
Work Policy
Work from office
78% employees reported
Monday to Saturday
61% employees reported
Flexible timing
62% employees reported
Within city
37% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
223 employees reported
Health insurance
199 employees reported
Office cab/shuttle
155 employees reported
Cafeteria
56 employees reported
View all benefits
About Glenmark Pharmaceuticals
Founded in1977 (48 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
--
Websiteglenmarkpharma.com
Primary Industry
Other Industries
--
Are you managing Glenmark Pharmaceuticals's employer brand? To edit company information,
claim this page for free
View in video summary
Glenmark is a leading global innovative pharmaceutical company committed to enriching lives worldwide. Our vision is to discover possibilities and make lives of patients better across the globe by developing cures for unmet medical needs. We have a rich pipeline of innovative molecules in various phases of development which are targeted in areas of oncology, respiratory and dermatology.
Managing your company's employer brand?
Claim this Company Page for FREE
Glenmark Pharmaceuticals Ratings
based on 2.9k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
1.4k
4
803
3
405
2
148
1
219
Category Ratings
3.7
Salary
3.7
Skill development
3.6
Company culture
3.6
Job security
3.6
Work-life balance
3.5
Work satisfaction
3.2
Promotions
Glenmark Pharmaceuticals is rated 3.9 out of 5 stars on AmbitionBox, based on 2.9k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Glenmark Pharmaceuticals
based on 2.8k reviews
3.8
Rated by 218 Women
Rated 3.7 for Job security and 3.6 for Skill development
3.9
Rated by 2.6k Men
Rated 3.7 for Salary and 3.7 for Skill development
Work Policy at Glenmark Pharmaceuticals
based on 397 reviews in last 6 months
Work from office
78%
Hybrid
17%
Permanent work from home
5%
Glenmark Pharmaceuticals Reviews
Top mentions in Glenmark Pharmaceuticals Reviews
+ 5 more
Compare Glenmark Pharmaceuticals with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.9k reviews | 4.0/5 based on 7k reviews | 4.1/5 based on 6.2k reviews | 4.1/5 based on 7.1k reviews |
Highly Rated for | No highly rated category | Skill development Company culture Work-life balance | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | Promotions | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 78% employees reported | Work from office 75% employees reported | Work from office 85% employees reported | Work from office 74% employees reported |
Rating by Women Employees | 3.8 Good rated by 218 women | 4.0 Good rated by 790 women | 4.0 Good rated by 375 women | 4.0 Good rated by 714 women |
Rating by Men Employees | 3.9 Good rated by 2.6k men | 4.1 Good rated by 5.9k men | 4.2 Good rated by 5.5k men | 4.1 Good rated by 6k men |
Job security | 3.6 Good | 3.6 Good | 3.7 Good | 3.7 Good |
View more
Glenmark Pharmaceuticals Salaries
Glenmark Pharmaceuticals salaries have received with an average score of 3.7 out of 5 by 2.9k employees.
Senior Officer
(948 salaries)
Unlock
₹1.9 L/yr - ₹8.8 L/yr
Officer
(840 salaries)
Unlock
₹1.1 L/yr - ₹6.5 L/yr
Junior Officer
(342 salaries)
Unlock
₹1.9 L/yr - ₹5.9 L/yr
Research Officer
(301 salaries)
Unlock
₹4.6 L/yr - ₹10.8 L/yr
Research Associate
(268 salaries)
Unlock
₹2.2 L/yr - ₹7.5 L/yr
District Sales Manager
(254 salaries)
Unlock
₹4.2 L/yr - ₹10.4 L/yr
Field Sales Officer
(245 salaries)
Unlock
₹2.8 L/yr - ₹6.5 L/yr
Production Officer
(245 salaries)
Unlock
₹1.8 L/yr - ₹6 L/yr
Medical Representative
(201 salaries)
Unlock
₹2.7 L/yr - ₹5.5 L/yr
Senior Research Officer
(172 salaries)
Unlock
₹7.5 L/yr - ₹15 L/yr
Glenmark Pharmaceuticals Interview Questions
Interview questions by designation
Top Glenmark Pharmaceuticals interview questions and answers
Get interview-ready with top interview questions
Glenmark Pharmaceuticals Jobs
Popular Designations Glenmark Pharmaceuticals Hires for
Popular Skills Glenmark Pharmaceuticals Hires for
Glenmark Pharmaceuticals News
View all
Glenmark Pharma Names Former Jindal Stainless CFO Anurag Mantri As President, Global CFO
- Glenmark Pharmaceuticals has appointed Anurag Mantri as President and Global CFO.
- Mantri's candidature for the position will be presented to the Audit Committee, Nomination and Remuneration Committee, and the Board for approval.
- Mantri has over 24 years of experience in business finance and strategic planning, previously working as the CFO of Jindal Stainless.
- Glenmark Pharma stock has fallen over 6.79% year-to-date and 47.42% in the past 12 months.
Bloomberg Quint | 7 Apr, 2025
Stock Market Live Updates 2 April 2025: Stock to buy today: HDFC Life Insurance Company (₹693.10)
- Lloyds Metals reported highest-ever sponge iron production, Kernex secured a new railway project, Surya Roshni reached highest monthly sales volume, Ritco Logistics secured contracts, Sansera Engineering's Associate Company collaborated with IITM.
- Glenmark Pharma launched Vancomycin Hydrochloride, Shree Cements started commercial production, Swelect Energy added a Solar PV Power Plant, Maruti's total passenger vehicle production increased, Zaggle entered into an agreement with Truecaller.
- Coal India to increase coal price, Warren Tea discussed potential merger, Blue Dart's income tax demand reduced, VIP Clothing upgraded its long-term debt rating, Sterling and Wilson secured new green energy projects.
- Quess Corp announced a record date for the demerger, Hind Copper achieved record ore production, SJVN completed a trial run of a green energy project, Max Healthcare expanded with a new facility, KEC International received new orders.
- Sandhar Tech acquired Aluminium die casting business, Power Grid emerged as successful bidder for inter-state transmission system, Power stocks saw surge in electricity consumption, JSW Energy added 3.6 GW of generation capacity, Raymond entered into a joint development agreement for a housing project.
HinduBusinessLine | 2 Apr, 2025
Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
- Mankind Pharma has launched a generic version of Empagliflozin, a diabetes medication, in India following the expiration of Boehringer Ingelheim's patent for the drug.
- The generic version is available under the brand names Empaglyde, Empagreat, and Dynaduo, in various strengths (10 mg to 25 mg).
- The launch aims to increase accessibility and affordability, with prices starting at Rs 5.49 for the 10 mg variant and Rs 9.90 for the 25 mg variant.
- Other companies, including Glenmark and Alkem Laboratories, have also introduced generic versions of Empagliflozin in India.
Bloomberg Quint | 12 Mar, 2025
Share Market Highlights 12 March 2025: Sensex, Nifty settle marginally lower; IndusInd Bank gains over 4%
- Stock market indices Nifty and Sensex open flat despite US stocks decline, SEBI issues show-cause notice to Kaynes Technology MD for insider trading concerns.
- Rupee trades nearly flat against US dollar amid volatile global sentiment and tariff uncertainties; markets open mixed with tech sector decline and resilience in auto and banking sectors.
- Shares of Zydus Lifesciences Limited and Easy Trip Planners Limited experience fluctuations; Zydus Lifesciences secures USFDA approval for Methenamine Hippurate Tablets.
- Adani group's funding access following US indictment improves, according to Fitch rating affirmation; Shubh Flexi Income plan by insurance company offers various financial goal options.
- Key financial firms increasingly investing in AI technologies like voice bots and workflow automation, yielding improved customer satisfaction and cost reductions.
- The telecommunications sector witnesses developments such as Airtel-SpaceX deal and regulatory considerations for potential US investments in India.
- Tech sell-off impacts stock markets, while banking stocks offer slight relief; PB Fintech invests in PB Healthcare and Glenmark introduces new products in India.
- Indian financial services company Mirae Asset announces expansion plans in India after acquiring Sharekhan, focusing on innovative solutions and customer-centric services.
- Various companies announce acquisitions, partnerships, and financial deals with positive, neutral, and negative impacts on their stocks and market perception.
- Market outlook predicts positive open despite global economic concerns, with potential volatility due to ongoing developments and global tensions.
HinduBusinessLine | 12 Mar, 2025
Glenmark expands diabetes portfolio with new Empagliflozin treatments
- Glenmark Pharmaceuticals has expanded its diabetes portfolio by launching new Empagliflozin treatments.
- The SGLT2 inhibitor and its combinations are designed to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) while reducing cardiovascular risks.
- The launch includes three options: Glempa (Empagliflozin 10mg/25mg) as a standalone treatment, Glempa-L (Empagliflozin with Linagliptin) as a dual-action therapy, and Glempa-M (Empagliflozin with Metformin) for stronger glycemic control.
- The market for Empagliflozin and combinations in India was valued at 642 crore for the 12-month period ending January 2025, according to IQVIA data.
HinduBusinessLine | 12 Mar, 2025
Stocks To Buy Today: JSW Energy, Crompton Greaves, Adani Power And More
- Analysts have recommended buying JSW Energy Ltd., Crompton Greaves Consumer Electricals Ltd., CG Power and Industrial Solutions Ltd., Adani Power Ltd., and Glenmark Pharmaceuticals Ltd. with potential upsides of up to 7%.
- JSW Energy can be purchased with a target price of Rs 545 and a stop loss of Rs 495.
- Crompton Greaves stock is recommended to be bought with a target price of Rs 365 and a stop loss of Rs 334.
- Adani Power stock is advised to be bought with a target price of Rs 528 and a stop loss of Rs 496.
Bloomberg Quint | 6 Mar, 2025
Stocks that will see action today: March 3, 2025
- Hyundai Motor India received a tax demand notice of Rs 15 crore from GST authorities for FY 2020-21 and FY 2021-22.
- ACME Solar plans a Rs 17,000 crore investment in hybrid and renewable capacities by 2026; considering entry into the nuclear energy sector.
- Glenmark Pharmaceuticals is recalling around 15 lakh bottles of Atomoxetine Capsules in the US market.
- Allied Blenders and Distillers forms ABD Maestro Pvt. Ltd. in collaboration with Ranveer Singh for luxury spirits markets.
- Enforcement Directorate issues FEMA violation notice to Paytm owner One97 Communications for its subsidiaries.
- NMDC reports a 17.8% increase in iron ore production to 4.62 million tonnes in February.
- NLC India wins a contract to develop a 200 MW wind power project from SJVN Ltd.
- Piramal Enterprises receives a demand notice of Rs 1,502 crore from Deputy Commissioner of State Tax, Maharashtra.
- Mahindra Holidays receives a demand of over Rs 17.5 crore from GST authority in Chennai for alleged turnover mismatch.
- Alpex Solar secures a Rs 210.71 crore order for Solar PV Modules and Solar Cells from SECI.
HinduBusinessLine | 3 Mar, 2025
Nifty Pharma Recovers As Dr. Reddy's, Glenmark Pharma Share Prices Lead
- Nifty Pharma erased losses despite weakness across most sectors of the market.
- The market-cap of pharmaceutical companies increased Rs 3,281.70 crore to Rs 15.83 lakh crore.
- Flight to safety is also one of the reasons behind the recovery of Nifty Pharma on Monday.
- Glenmark Pharmaceuticals settled the lawsuits related to generic drug Zeita and Vytorin against its US subsidiary.
Bloomberg Quint | 24 Feb, 2025
Glenmark Pharma Q3 Results Review— Regulatory Compliance Critical For Turnaround In U.S. Says ICICI Securities
- Glenmark Pharmaceuticals' Q3 FY25 result was dragged by weak show in India, US, and RoW markets.
- Revival in the US hinges on its ability to adhere with regulatory standards and timely approval of gFlovent and other assets.
- India biz revenue run-rate slowed down in Q3 FY25 and Glenmark's management now anticipates sales from India to grow at 9-10%.
- The brokerage maintains 'Reduce' on Glenmark Pharma with a lower target price of Rs 1,265, based on 22x FY26E EPS.
Bloomberg Quint | 18 Feb, 2025
Stock Market Highlights 17 February 2025: Sensex, Nifty crawl up to close marginally higher
- Sensex is getting support near 75,400 with resistance around 77,100. Nifty Bank index's immediate outlook is unclear, finding support near 48,700. Long-term supports include Nifty 50 at 22,500-22,000, Sensex at 74,000-72,000, and Nifty Bank at 48,000-46,600.
- Stock markets rebounded with Sensex closing higher by 57 points, driven by value buying in blue-chip stocks. Indian rupee depreciated against the US dollar due to foreign fund outflows and global uncertainty impacting the forex market.
- Eurobank partners with LTIMindtree to establish a Global Delivery Centre in Pune, enhancing banking operations and IT services. Various stocks like KIOCL Limited and Shakti Pumps (India) witnessed fluctuations in trading on the NSE.
- Arrow Capital, regulated by the Dubai Financial Services Authority (DFSA), has expanded its services globally. InCred acquires Arrow Capital, broadening its financial solutions globally.
- Quality Power Electrical Equipments' IPO saw 62% subscription on day 1, with Ajax Engineering IPO listing at a slight discount. Glenmark Pharma Chairman discussed US tariffs and upcoming launches.
- Financial highlights for various companies, such as Swan Energy, Kitex Garments, and UFLEX, with their net profits and revenues compared year-over-year.
- Earnings data for Q3FY25 & 9MFY25 showed growth in pre-provision operating profit and profit after tax, indicating resilience in the lending sector.
- Q3FY25 results for BSE500 and Nifty companies were modest, with slight improvement sequentially. Earnings downgrades continued, albeit at a slower pace, impacting valuations.
- Institutional flows remained resilient despite market corrections. Macroeconomic events like Federal Reserve meeting minutes and China loan rates are expected to influence market focus in the upcoming week.
- Nifty 50 closed with a loss of 2.68%, while Nifty Bank maintained a 2.11% loss. Weekly fund-flow activities showcased FIIs selling equities and DIIs buying in the cash segment.
HinduBusinessLine | 17 Feb, 2025
Powered by
Compare Glenmark Pharmaceuticals with
Zydus Lifesciences
4.1
Sun Pharmaceutical Industries
4.0
Aurobindo Pharma
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.1
Alembic Pharmaceuticals
4.0
Abbott
4.1
Alkem Laboratories
3.9
Ipca Laboratories
3.9
Torrent Pharmaceuticals
3.9
Mankind Pharma
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
3.9
DIVI'S Laboratories
3.7
Wockhardt
3.9
Sanofi
4.2
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Glenmark Pharmaceuticals
Cipla
Manufacturing, Pharma
4.1
• 7.1k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.2k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6.1k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.9k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.5k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.9
• 3.4k reviews
Viatris
Manufacturing, Pharma
4.1
• 3.2k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.2k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.1k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.9k reviews
Glenmark Pharmaceuticals FAQs
When was Glenmark Pharmaceuticals founded?
Glenmark Pharmaceuticals was founded in 1977. The company has been operating for 48 years primarily in the Pharma sector.
Where is the Glenmark Pharmaceuticals headquarters located?
Glenmark Pharmaceuticals is headquartered in Mumbai, Maharashtra.
How many employees does Glenmark Pharmaceuticals have in India?
Glenmark Pharmaceuticals currently has more than 12,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Glenmark Pharmaceuticals based on the number of reviews submitted on AmbitionBox.
Does Glenmark Pharmaceuticals have good work-life balance?
Glenmark Pharmaceuticals has a Work-Life Balance Rating of 3.6 out of 5 based on 2,900+ employee reviews on AmbitionBox. 74% employees rated Glenmark Pharmaceuticals 4 or above, while 26% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Glenmark Pharmaceuticals work-life balance reviews for more details
Is Glenmark Pharmaceuticals good for career growth?
Career growth at Glenmark Pharmaceuticals is rated as moderate, with a promotions and appraisal rating of 3.2. 26% employees rated Glenmark Pharmaceuticals 3 or below, while 74% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Glenmark Pharmaceuticals promotions/appraisals reviews for more detailed insights.
What are the cons of working in Glenmark Pharmaceuticals?
Working at Glenmark Pharmaceuticals does have some drawbacks that potential employees should consider. The company is poorly rated for promotions / appraisal, based on 2,900+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
